-- The Federal Trade Commission has opened an investigation into Teva
Pharmaceutical Industries over its patent practices, the Washington Post
reported on Monday.
-- The probe focuses on the Israeli company's refusal to withdraw patents for
asthma inhalers and treatments for chronic obstructive pulmonary
disease from a federal registry called the Orange Book, according to the Post.
-- The FTC claims Teva made small modifications to keep the patents in the registry
and stifle competition, the Post reported.
-- Teva spokesperson Kelley Dougherty told The Wall Street Journal that the
company's patents are properly listed and that Teva "continues to stand
behind the company's intellectual property."
Full article at https://www.washingtonpost.com/health/2024/07/01/teva-patent-pharma-generic-inhaler/
Write to Victor Swezey at victor.swezey@wsj.com
(END) Dow Jones Newswires
07-01-24 1249ET